The Leishmania infantum Acidic Ribosomal Protein P0 Administered as a DNA Vaccine Confers Protective Immunity to Leishmania major Infection in BALB/c Mice

Infection and Immunity

Volumn 71, Issue 11, 2003, Pages 6562-6572

  Iborra, Salvador ^a   Soto, Manuel ^a   Carrión, Javier ^a   Nieto, Ana ^b   Fernández, Edgar ^a   Alonso, Carlos ^a   Requena, Jose M ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; DNA VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 12; LEISHMANIA INFANTUM ACIDIC RIBOSOME PROTEIN PO; PLASMID DNA; PLASMID DNA3 LIESHMANIA INFANTUM RIBOSOME ACIDIC PROTEIN PO; RIBOSOME PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG FORMULATION; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; LEISHMANIA DONOVANI; LEISHMANIA MAJOR; LEISHMANIASIS; LYMPH NODE CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; SPLEEN CELL; VACCINATION;

ANIMALS; ANTIBODIES, PROTOZOAN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; IMMUNIZATION; IMMUNOGLOBULIN G; INTERFERON TYPE II; INTERLEUKIN-4; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; MICE; MICE, INBRED BALB C; PHOSPHOPROTEINS; PROTOZOAN VACCINES; RIBOSOMAL PROTEINS; VACCINES, DNA;

EID: 0242349620     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.71.11.6562-6572.2003     Document Type: Article

References (33)

1. + T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J. Immunol. 168:3992-4000.
2. Buffet, P. A., A. Sulahian, Y. J. Garin, N. Nassar, and F. Derouin. 1995. Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice. Antimicrob. Agents Chemother. 39:2167-2168.
3. Campos-Neto, A., J. R. Webb, K. Greeson, R. N. Coler, Y. A. W. Skeiky, and S. G. Reed. 2002. Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice. Infect. Immun. 70:2828-2836.
4. Chang, K. P., S. G. Reed, B. S. McGwire, and L. Soong. 2003. Leishmania model for microbial virulence: the relevance of parasite multiplication and pathoantigenicity. Acta Trop. 85:375-390.
5. Chatterjee, S., S. Singh, R. Sohoni, V. Kattige, C. Deshpande, S. Chiplunkar, N. Kumar, and S. Sharma. 2000. Characterization of domains of the phosphoriboprotein P0 of Plasmodium falciparum. Mol. Biochem. Parasitol. 107:143-154.
6. Chatterjee, S., S. Singh, R. Sohoni, N. J. Singh, A. Vaidya, C. Long, and S. Sharma. 2000. Antibodies against ribosomal phosphoprotein P0 of Plasmodium falciparum protect mice against challenge with Plasmodium yoelii. Infect. Immun. 68:4312-4318.
7. Coffman, R. L., D. A. Lehman, and P. Rothman. 1993. Mechanism and regulation of immunoglobulin isotype switching. Adv. Immunol. 54:229-270.
8. Coler, R. N., Y. A. W. Skeiky, K. Bernards, K. Greeson, D. Carter, C. D. Cornellison, F. Modabber, A. Campos-Neto, and S. G. Reed. 2002. Immunization with a polyprotein vaccine consisting of the T-cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect. Immun. 70:4215-4225.
9. Gurunathan, S., D. M. Klinman, and R. A. Seder. 2000. DNA vaccines: immunology, application, and optimization. Annu. Rev. Immunol. 18:927-974.
10. Gurunathan, S., D. L. Sacks, D. R. Brown, S. L. Reiner, H. Charest, N. Glaichenhaus, and R. A. Seder. 1997. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J. Exp. Med. 186:1137-1147.
11. + T cells. J. Immunol. 165:915-924.
12. Handman, E. 2001. Leishmaniasis: current status of vaccine development. Clin. Microbiol. Rev. 14:229-243.
13. Herwaldt, B. L. 1999. Leishmaniasis. Lancet 354:1191-1199.
14. Julia, V., M. Rassoulzadegan, and N. Glaichenhaus. 1996. Resistance to Leishmania major induced by tolerance to a single antigen. Science 274:421-423.
15. Laemmli, U. K. 1970. Cleavage of structured proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
16. Lai, W. C., and M. Bennett. 1998. DNA vaccines. Crit. Rev. Immunol. 18:449-484.
17. Louis, J., H. Himmelrich, C. Parra-Lopez, F. Tacchini-Cottier, and P. Launois. 1998. Regulation of protective immunity against Leishmania major in mice. Curr. Opin. Immunol. 10:459-464.
18. Melby, P. C. 2002. Vaccination against cutaneous leishmaniasis: current status. Am. J. Clin. Dermatol. 3:557-570.
19. Melby, P. C., G. B. Ogden, H. A. Flores, W. Zhao, C. Geldmacher, N. M. Biediger, S. K. Ahuja, J. Uranga, and M. Melendez. 2000. Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library. Infect. Immun. 68:5595-5602.
20. Melby, P. C., J. Yang, W. Zhao, L. E. Perez, and J. Cheng. 2001. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect. Immun. 69:4719-4725.
21. Mendez, S., Y. Belkaid, R. A. Seder, and D. Sacks. 2002. Optimization of DNA vaccination against cutaneous leishmaniasis. Vaccine 20:3702-3708.
22. Mendez, S., S. Gurunathan, S. Kamhawi, Y. Belkaid, M. A. Moga, Y. A. W. Skeiky, A. Campos-Neto, S. Reed, R. A. Seder, and D. Sacks. 2001. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge. J. Immunol. 166:5122-5128.
23. Menon, J. N., and P. A. Bretscher. 1996. Characterization of the immunological memory state generated in mice susceptible to Leishmania major following exposure to low doses of L. major and resulting in resistance to a normally pathogenic challenge. Eur. J. Immunol. 26:243-249.
24. Rafati, S., A.-H. Salmanian, T. Taheri, M. Vafa, and N. Fasel. 2001. A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major. Vaccine 19:3369-3375.
25. Ramshaw, I. A., and A. J. Ramsay. 2000. The prime-boost strategy: exciting prospects for improved vaccination. Immunol. Today 21:163-165.
26. Requena, J. M., C. Alonso, and M. Soto. 2000. Evolutionarily conserved proteins as prominent immunogens during Leishmania infections. Parasitol. Today 16:246-250.
27. Sacks, D., and N. Noben-Trauth. 2002. The immunology of susceptibility and resistance to Leishmania major in mice. Nat. Rev. Immunol. 2:845-858.
28. Shi, P. Y., N. Maizels, and A. M. Weiner. 1997. Recovery of soluble, active recombinant protein from inclusion bodies. BioTechniques 23:1036-1038.
29. Sjölander, A., T. M. Baldwin, J. M. Curtis, and E. Handman. 1998. Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for a generation of immunity to leishmaniasis. J. Immunol. 160:3949-3957.
30. Skeiky, Y. A. W., D. R. Benson, M. Elwasila, R. Badaro, J. M. Burns, Jr., and S. G. Reed. 1994. Antigens shared by Leishmania species and Trypanosoma cruzi: immunological comparison of the acidic ribosomal P0 proteins. Infect. Immun. 62:1643-1651.
31. Skeiky, Y. A. W., M. Kennedy, D. Kaufman, M. M. Borges, J. A. Guderian, J. K. Scholler, P. J. Ovendale, K. S. Picha, P. J. Morrissey, K. H. Grabstein, A. Campos-Neto, and S. G. Reed. 1998 LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile. J. Immunol. 161:6171-6179.
32. Soto, M., J. M. Requena, and C. Alonso. 1993. Isolation, characterization and analysis of the expression of the Leishmania ribosomal P0 protein genes. Mol. Biochem. Parasitol. 61:265-274.
33. Soto, M., J. M. Requena, L. Quijada, F. Guzman, M. E. Patarroyo, and C. Alonso. 1995. Identification of the Leishmania infantum P0 ribosomal protein epitope in canine visceral leishmaniasis. Immunol. Lett. 48:23-28.